Psychedelic Medicines in Major Depression: Progress and Future Challenges

Psychedelic compounds — including plant preparations, fungi and synthetic molecules — produce profound alterations in consciousness and have millennia‑long ritual and medicinal uses in many indigenous cultures. The terminology and conceptual framing of these substances remain contested: early Western research distinguished psycholytic (low‑dose, therapy‑assisting) and psychedelic (high‑dose, spiritual experience) paradigms, and contemporary work generally focuses on serotonergic psychedelics (LSD, psilocybin, DMT/ayahuasca) that act largely at 5‑HT2A receptors. Renewed scientific interest since the 1990s has reflected both advances in neuropharmacology and the perceived need for novel psychiatric treatments. Bouso and colleagues set out to review recent clinical trials that have tested psychedelic medicines for anxiety and depressive disorders, to summarise proposed neurobiological mechanisms that might underlie antidepressant effects, and to outline the main challenges facing clinical development and implementation. The chapter is a narrative synthesis rather than a systematic review and aims to integrate clinical findings, neuroimaging and molecular data with practical and regulatory considerations for translating psychedelic‑assisted therapies into clinical practice.

The extracted text does not present a dedicated Methods section or a formal search strategy; the paper is a narrative review summarising historical background, published clinical trials, mechanistic studies and implementation issues. Accordingly, the researchers synthesised findings from randomized controlled trials (including crossover and parallel designs), open‑label studies and preclinical work, and discussed neuroimaging, molecular and physiological evidence relevant to antidepressant mechanisms. Where clinical trials are described, the review reports key design features as stated in those trial reports (for example, sample sizes, dosing regimens and outcome scales) but does not report a prespecified inclusion/exclusion criterion for which studies were reviewed or a formal risk‑of‑bias assessment. Because the paper is a chapter-style synthesis rather than a systematic meta-analysis, no pooled statistical methods or meta‑analytic models are reported in the extracted text.

Clinical trial evidence: The chapter summarises two bodies of clinical work: trials of psychedelics for anxiety/depression in the context of life‑threatening illness, and trials in primary major depressive disorder (MDD) and treatment‑resistant depression (TRD). Since 2011, four randomized, double‑blind, placebo‑controlled, crossover trials investigated LSD (one trial) or psilocybin (three trials) in patients with cancer‑related anxiety/depression; of these, three psilocybin trials assessed depressive symptoms specifically. Sample sizes in these controlled trials ranged from 12 to 51 patients, and oral psilocybin doses were typically 14–30 mg per 70 kg. All three psilocybin trials reported significant reductions in Beck Depression Inventory (BDI) scores at 6 months; two trials that used the Hospital Anxiety and Depression Scale (HADS) also reported significant HADS reductions at 6 months. Reported adverse events were generally transient (acute anxiety/distress, sensorimotor illusions, transient psychotic‑like symptoms, headache, nausea/vomiting) with mild increases in blood pressure and heart rate; no serious safety signals were reported in those trials. For MDD and TRD outside the cancer setting, results are more heterogeneous but promising. An open‑label ayahuasca study initially treated six patients and later reported a final sample of 17 patients with MDD; a single oral dose (2.2 mL/kg; 0.8 mg/mL DMT in the pilot and a separate RCT dose of 1 mL/kg; 0.36 mg/mL DMT) was associated with significant reductions on HAM‑D, MADRS and the anxiety–depression subscale of the BPRS at 1, 7 and 21 days in the open‑label work, and in the randomized, placebo‑controlled trial (n=29) ayahuasca produced significant reductions in MADRS at 1, 2 and 7 days and in HAM‑D at 7 days. In that controlled ayahuasca trial, ayahuasca was also associated with subacute normalisation of low baseline cortisol (hypocortisolaemia) and increases in brain‑derived neurotrophic factor (BDNF); increases in BDNF were negatively correlated with antidepressant response and appeared modulated by acute cortisol increases. Adverse effects were mostly transient nausea and vomiting; no serious adverse events were reported. An open‑label psilocybin study in 12 TRD patients administered two oral doses (10 mg and 25 mg, 7 days apart) and reported significant BDI reductions at 1 week and 3 months, and improvements on QIDS and SHAPS up to 6 months in an expanded follow‑up. Neuroimaging in that study showed decreased amygdala blood flow and changes in functional connectivity (increased connectivity within elements of the default‑mode network and between ventromedial prefrontal and inferior lateral parietal regions, and decreased parahippocampal–prefrontal connectivity), which the authors related to clinical improvement; social‑cognitive gains and personality changes (reduced pessimism and neuroticism; increased extraversion and openness) were also reported. A randomized waitlist‑controlled psilocybin trial in 22 MDD patients compared immediate versus delayed dosing (two oral doses of 20 and 30 mg per 70 kg). Significant group differences on the GRID‑Hamilton Depression Rating Scale favoured the immediate group at 1 and 4 weeks. Clinically, 62% of participants in the immediate condition met response criteria and 39% met remission criteria at both 1 and 4 weeks, whereas no patients in the delayed condition achieved clinically significant response or remission in the reported timeframe. Reported adverse events across psilocybin studies included transient anxiety, confusion, nausea, headache and some autonomic or perceptual effects; serious adverse events were not reported in these small trials. The authors stress that open‑label designs and small sample sizes limit causal inference and generalisability, though several controlled trials nonetheless showed antidepressant effects. Neurobiological mechanisms: The review emphasises that psychedelics are not mechanistically uniform and classifies them broadly into serotonergic hallucinogens (indolamines such as LSD, psilocybin, DMT), dissociative anaesthetics (ketamine) and entactogens (MDMA). For serotonergic psychedelics, agonism at the 5‑HT2A receptor is held central to the characteristic subjective and neurophysiological effects; antagonism at 5‑HT2A reduces or blocks these effects in imaging and pharmacological studies. Many psychedelics have multi‑target profiles: LSD interacts with multiple serotonin subtypes and dopamine receptors and binds to trace amine‑associated receptor 1 (TAAR1); DMT is an agonist at the sigma‑1 (σ1) receptor; and the β‑carbolines in ayahuasca (harmine, tetrahydroharmine, harmaline) are reversible MAO‑A inhibitors with additional receptor interactions. Mechanistic effects that could relate to antidepressant outcomes include rapid promotion of neuroplasticity and neurogenesis. Serotonergic psychedelics appear to enhance glutamatergic tone and AMPA receptor activity following 5‑HT2A activation, increasing cortical electrical activity and information processing; DMT and LSD have been described as 'psychoplastogens' for their capacity to promote structural and functional plasticity (increased c‑fos expression, enhanced BDNF expression in prefrontal regions). Neuroimaging findings are heterogeneous: PET/SPECT studies generally report increased perfusion/metabolism in prefrontal and medial temporal regions and amygdala, whereas fMRI studies report both decreases and increases in connectivity of networks including the default‑mode network (DMN), executive control and attention networks. A convergent pattern described is increased prefrontal and limbic activity alongside decreases in key DMN hubs, which could relate to reduced rumination. Psychedelics also reduce amygdala reactivity to negative emotional stimuli and can alter emotion recognition, potentially improving social cognition. Additional lines of evidence include anti‑inflammatory and neuroprotective effects seen in preclinical models: DOI showed potent anti‑inflammatory activity (EC50 ~15 picomolar) in vitro and in systemic models; proteomic work with 5‑MeO‑DMT downregulated inflammation‑associated proteins in human cerebral organoids. DMT and β‑carbolines may exert neuroprotective effects via σ1 receptor modulation and MAO inhibition respectively. Psychedelics also produce neuroendocrine changes (oxytocin and cortisol release), with cortisol increases noted after ayahuasca that moved hypocortisolaemic patients toward normal levels for at least 48 hours.

Bouso and colleagues identify several practical and scientific challenges that must be addressed for psychedelic medicines to become established treatments. Chief among these is the small size and selective samples of published trials — the mean sample across trials described is about 26 subjects — and strict inclusion/exclusion criteria that commonly exclude people with a history of psychosis or bipolar disorder. The authors note that many trials preferentially recruit participants with prior psychedelic experience (up to 75% in two trials and 50% in two others), which may bias safety and tolerability findings; they argue for pragmatic trials that include psychedelic‑naïve participants to improve external validity. The integration of psychotherapy and drug administration poses additional challenges: psychedelic sessions are long and require trained support (reported session durations are roughly 5–6 hours for ayahuasca, 6–8 hours for psilocybin and 12–15 hours for LSD), which has implications for clinical infrastructure, workforce training and cost. The authors compare this to the esketamine model, where patients are monitored for at least 2 hours post‑dose, and suggest a supervised‑setting model is likely to be required for serotonergic psychedelics as well. Regulatory and cultural issues are also highlighted: ayahuasca already has widespread ritual and medicinal use in parts of South America and beyond, so biomedical applications may need to coexist and enter dialogue with traditional practices, and local legal frameworks (including decriminalisation movements) will influence how these treatments are delivered and governed. Despite these hurdles, the authors consider psychedelic‑assisted psychotherapy an innovative approach that combines psychotherapeutic and pharmacological mechanisms and note that several mechanistic pathways (neuroplasticity, anti‑inflammatory effects, neuroendocrine modulation) remain incompletely explored. They recommend replication of controlled findings by multiple research groups, larger pragmatic and comparative trials versus established treatments, and further mechanistic research to clarify how these drugs might exert sustained antidepressant effects.